This is the standing evidence sheet for Tonix Pharmaceuticals Holding (TNXP): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Tonix Pharmaceuticals Holding is priced at 15.7× its annual sales (typical for this company over its past decade: 34.1×).
The tape: what the stock itself has done
- Last price: $12.34 · 80% below its 52-week high
- Past 6 months: -24.1% · past 12 months: -73.5%
- Day-to-day temperament: jumpy (annualized volatility 85%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2023 | $0.0B | , | -1523.9% | $-6.85 |
| FY2024 | $0.0B | +29.9% | -1354.3% | $-176.6 |
| FY2025 | $0.0B | +29.8% | -959.1% | $-14.57 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net product revenue ($M) | 0.0 | 10.1 | 13.1 | 28 to 50 | 48 to 102 |
| Net revenue growth (%) | N/A | N/M | +30 | 114 | 78 |
| Grant/other income ($M) | 2.6 | 2.6 | 3.0 | 3 to 5 | 2 to 5 |
| Total revenue ($M) | 2.6 | 12.7 | 16.1 | 31 to 54 | 50 to 107 |
| Operating margin (%) | -N/M | -N/M | -959 | -350 to -250 | -180 to -80 |
| GAAP diluted EPS ($) | -6.85 | -176.60 | -14.57 | -8.50 to -4.00 | -6.00 to -1.50 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
Read the full report on Tonix Pharmaceuticals Holding in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-08-11. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
